Add like
Add dislike
Add to saved papers

Downregulation of type 3 inositol (1,4,5)-trisphosphate receptor decreases breast cancer cell migration through an oscillatory Ca 2+ signal.

Oncotarget 2017 September 23
Breast cancer remains a research priority due to its invasive phenotype. Although the role of ion channels in cancer is now well established, the role of inositol (1,4,5)-trisphosphate (IP3 ) receptors (IP3 Rs) remains enigmatic. If the three IP3 Rs subtypes expression have been identified in various cancers, little is known about their physiological role. Here, we investigated the involvement of IP3 R type 3 (IP3 R3 ) in the migration processes of three human breast cancer cell lines showing different migration velocities: the low-migrating MCF-7 and the highly migrating and invasive MDA-MB-231 and MDA-MB-435S cell lines. We show that a higher IP3 R3 expression level, but not IP3 R1 nor IP3 R2, is correlated to a stronger cell line migration capacity and a sustained calcium signal. Interestingly, silencing of IP3 R3 highlights an oscillating calcium signaling profile and leads to a significant decrease of cell migration capacities of the three breast cancer cell lines. Conversely, stable overexpression of IP3 R3 in MCF-7 cells significantly increases their migration capacities. This effect is completely reversed by IP3 R3 silencing. In conclusion, we demonstrate that IP3 R3 expression level increases the migration capacity of human breast cancer cells by changing the calcium signature.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app